ClinicalTrials.Veeva

Menu

Effect of CGM on Glucose Control in Non-insulin-treated Patients with Type 2 Diabetes Mellitus (CONVERT)

S

Sinocare

Status

Not yet enrolling

Conditions

Diabetes Mellitus

Treatments

Device: Sinocare iCan I3 CGM
Device: Sinocare jinzhi+Blood glucose meter

Study type

Interventional

Funder types

Industry

Identifiers

NCT06587438
SN-CGM-PO-001

Details and patient eligibility

About

The clinical value of CGM for diabetic patients undergoing insulin therapy has been widely recognized, but the evidence-based support for its use in non-insulin-treated type 2 diabetic patients remains insufficient. The primary objective of this study is to evaluate the effect of real-time continuous glucose monitoring (CGM) compared with self-monitoring of blood glucose on glycemic control in adults with non-insulin treated type 2 diabetes.

Enrollment

160 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • (1)Subjects aged ≥18 years at screening (based on the day of signing the informed consent form) and of any gender
  • (2)Patients diagnosed with type 2 diabetes
  • (3)Prior to the screening, glycemic control was suboptimal with diet, exercise control, and oral medication or glucagon-like peptide-1RA (GLP-1RA) therapy maintained for more than 3 months, 7.5%≤HbA1c≤10%
  • (4)Subjects voluntarily sign an informed consent form

Exclusion criteria

  • (1)Patients treated with insulin within 3 months prior to screening
  • (2)Currently or have used a CGM device within 3 months prior to enrollment
  • (3)Serious skin disease at the sensor placement site, allergy to tape or adhesives
  • (4)Pregnant females, those with a positive pregnancy test result at screening, or those who plan to become pregnant during the study
  • (5)Those who are participating or will participate in other clinical trials
  • (6)Those who, in the opinion of the investigator, should not participate in this clinical trial, such as: ①those who have a history of eye trauma or other diagnosed eye diseases resulting in visual impairment, etc.; ②those who are unwilling or unable to fully understand or cooperate due to speech disorders; ③those who suffer from mental disorders

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

160 participants in 2 patient groups

Real-time Continuous glucose monitor
Experimental group
Description:
In the first two weeks of every four-week period, rt-CGM is used to monitor blood glucose levels, while in the latter two weeks, SBMG is employed for usual care
Treatment:
Device: Sinocare iCan I3 CGM
Self-monitoring of blood glucose
Active Comparator group
Description:
Using SMBG for usual care only.
Treatment:
Device: Sinocare jinzhi+Blood glucose meter

Trial contacts and locations

0

Loading...

Central trial contact

Jian Zhou, Prof.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems